Progenra, Inc. pursues novel approaches to exploit the ubiquitin proteasome system for drug discovery in numerous therapeutic areas. Its UbiPro™ Drug Discovery Platform is a multi-faceted approach based on the physiological milieux in which enzymes of the ubiquitin proteasome system interact with their substrates. This approach has led to breakthroughs in developing drug candidates for evaluation and progression in the clinic. Progenra’s expertise in developing small molecule E3 ligase modulators is being harnessed to create novel classes of PROTAC molecules to expand the scope of this promising new avenue of proteostasis-based therapeutics.
Progenra’s mission is to leverage its expertise in the ubiquitin proteasome system and cellular protein regulation, acquired over several years, to discover and develop novel, first in class medicines to fill unmet needs in a spectrum of therapeutic areas.